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Abstract  
Autoimmune neutropenia (AIN) is the frequent cause of neutropenia in infants and children. AIN is 
associated with a reduced neutrophil count, which is due to aberrant cell-mediated or humoral immune 
response. In this review, we will discuss the available diagnostic approaches and management of the 
diseases. We collected data from PubMed, Google Scholar, Medline, Web of Science databases, using 
a group of key words, such as neutropenia, autoimmune, diagnosis and management from 2000 until 
2019. The most important aspects of primary assessment in the affected children were family history 
and physical examinations. Diagnostic methods in this disease are granulocyte indirect agglutination 
test (GAT) and granulocyte immunofluorescence test (GIFT). However, the sensitivity and specificity 
of these tests are low. In these patients, injection of granulocyte-colony stimulating factor (G-CSF), is 
the first line of treatment. Despite low prevalence, autoimmune neutropenia is a clinically significant 
disease and it is critical to identify it and pursue effective treatment in these patients. 
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Introduction 
Overview of autoimmune neutropenia 
     Neutropenia is the reduction of absolute neutrophil 
count in the peripheral blood  [1], and it is a relatively 
common blood disorder during childhood  [2]. The 
normal range of neutrophils in peripheral blood 
depends on one’s race and ethnicity and age. In 
Caucasian children who are one year old or more, 
neutropenia is defined as a neutrophil count of less than 
1500 cell/μL. In infants who are  less than one year old, 
1000 cell/μL is considered the minimum normal count 
of neutrophil. Neutrophil count in peripheral blood of 
most Caucasians and Asians ranges from 1500 to 1700 
cell/μL [1]. At least in 5% of the African people, their 
neutrophil count can be less than 1500 cell/μL, which is 
related to their Duffy negative blood group, also known 
as racial pseudo- neutropenia. When the neutrophils 
count is less than 500 cell/μL, neutropenia is considered 
as severe and clinically significant [3]. Neutropenia, like 
other reduced hematopoietic cell lines, can be researched 
in the sense of reduced production, increased circulatory 
marginalization, increased consumption, or destruction. 
Classification can be done based on ethiology. There are 
broad categories for neutropenia including infectious, 
drug-mediated, malignancy, congenital, and 
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autoimmune neutropenia. The cause of transient 
neutropenia can be related to viral infections, which 
lasts less than three months and occurs frequently. 
Autoimmune neutropenia is considered as a chronic 
disorder that lasts at least three months. In infants and 
children, the distinction between autoimmune 
neutropenia and benign chronic neutropenia is difficult 
and usually defined together. Many children who are 
diagnosed with chronic and idiopathic neutropenia are 
explained as secondary to autoimmune neutropenia. In 
most patients, the common feature of these conditions, 
is a benign course with good clinical characteristics. 
Unlike congenital neutropenia which is associated with 
reduced or loss of bone marrow production, patients 
with increased neutrophil destruction, such as 
autoimmune neutropenia have much lower rates of 
infection and mortality and rarely suffer from severe 
infections. During an acute infection, an appropriate 
augment in the neutrophil count can be helpful for 
diagnosis. Relatively mild, common childhood 
infections, such as upper respiratory tract infections, ear 
or skin infections might appear during the disease and 
in severe neutropenia, oral ulcers may also occur [4]. 
Autoimmune neutropenia is the most common 
childhood neutropenia [5]. The prevalence of this 
disease is 1 in 100,000 children per year [6, 7]. Since 
most children with this condition have a mild course, 
mostlikely a complete blood cell counts are never 
evaluated. Therefore, it seems the actual incidence of 
the disease is higher than the reported cases. 
     Autoimmune neutropenia in childhood occurs 
between 7-9 months and it is a common cause of 
neutropenia in children [8]. Generally, these disorders 
usually appear in the first two years of life [9]. On the 
whole, there is no clear relationship between the 
prevalence of autoimmune neutropenia and gender. A 
Japanese study of 18 patients reported that the age of 
onset is between 7 and 8 months of age [10]. But other 
data from a study on 157 patients revealed that most  
people experience the disease in the first 8 to 9 months 
of  their life; however, disease diagnosis is confirmed 
after 3-4 months from the time of onset [5, 7]. The 
disease appears in all patients before the age of 5, and 
in 82% of the cases before 18 months. Three children 
developed the disease in the first three months of their 
life after alloimmune neutropenia diagnoses were ruled 
out. The disease spontaneously disappears in most 5-
year-old children (more than 95%), lasting 18 to 24 
months after the time of diagnosis [10, 11]. Children with 
autoimmune neutropenia who are older than 5 years are 
at higher risk for other immune or autoimmune diseases 
[1].  
     The main mechanism of this rare blood disorder is 
opsonization, in which neutrophils are destroyed by 
autoantibodies. This process accelerates the 
phagocytosis of antibody-coated neutrophils. Moreover, 
anti-neutrophil antibodies affect the function of target 
proteins and impair the function of neutrophils [12].  
     Autoimmune neutropenia is classified into primary 
and secondary. Primary immune-neutropenia is 
relatively common amongst infants and children and this 
condition is rather benign and self-limited [9]. Secondary 
immune-neutropenia is relatively common in adults and 
is associated with different pathological diseases 
including: infectious diseases, autoimmune diseases, 
hematological malignancies, transplantation, and drug-
allergy [13]. Immune neutropenia in the neonatal period 
can be either alloimmune or autoimmune. Alloimmune 
neutropenia occures due to alloimmunization against 
neutrophil-specific antigens which do not appear on 
maternal white blood cells [11]. After the neonatal 
period, perhaps most children with autoimmune 
neutropenia have antibodies that are directed against 
neutrophil surface antigens. The outcome of neutropenia 
is the result of peripheral destruction of antibody-coated 
neutrophils. In the spleen of patients who are affected by 
autoimmune neutropenia, neutrophil phagocytosis was 
also detected   [10]. The definite mechanism of 
autoantibody production is unknown. Most likely, 
antibodies that are produced against foreign antigens, 
such as viruses, have cross-reaction with self-antigens 
[14]. There is no specific viral antigen related to 
autoimmune neutropenia. For instance, a study of 240 
sick infants and children found no significant association 
between autoimmune neutropenia and parvovirus B19 
infection [4]. More than half of patients with 
autoimmune neutropenia have severe neutropenia. 
Leukopenia may also occur, but in more than half of the 
cases the total white blood cells count is normal, while 
monocytosis can also be present [7]. Most researches on 
the bone marrow of patients with primary autoimmune 
neutropenia have normal to increased cellularity, which 
indicates increased myloid to erythroid ratio without a 
reduction in mature granulocyte precursors [7, 15]. In a 
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study of 240 patients with certain autoimmune 
neutropenia, after assessing 133 bone marrow 
examinations, only 3% showed hypocellular bone 
marrow. In such cases, bone marrow examinations 
shows that antibodies bind to granulocyte precursors in 
addition to binding to mature neutrophils in the 
peripheral blood. This antibody-related destruction 
against fragmented neutrophils and the basic forms, 
might mimic the process of maturation arrest in the 
myelocyte and metamyelocyte stages [4]. 
     Children with another immune cytopenia, such as 
immune- thrombocytopenia, autoimmune hemolytic 
anemia and chronic autoimmune neutropenia are more 
likely to have a secondary form, which is associated 
with other chronic diseases or immunological processes 
well past the age of 5 [11]. Secondary autoimmune 
neutropenia can appear at any age with different clinical 
courses. In older children and adolescents (more 
common in females) there is an increased association 
with other autoimmune diseases and less likelihood of 
self-remission [9]. Therefore, patients who develop 
autoimmune neutropenia after childhood, their disease 
lasts more than 3 years, and also, those with other 
congenital cell lineage abnormalities should be 
evaluated for secondary forms [16]. 
Diagnostic evaluation 
     When a child presents with neutropenia, the 
emphasis should be on determining the risk for 
infection and managing it. However, the definition of 
the main pathology plays an important role in 
estimating the chance of infection in childhood 
neutropenia. A complete medical history, physical 
examination, and family history can limit the 
differential diagnoses in the affected children. Usually, 
for a child with a history of autoimmune neutropenia, 
more laboratory tests and bone marrow examinations 
are not performed. In peripheral blood, anti-neutrophil 
antibodies can be helpful to diagnose autoimmune 
neutropenia. However, this test has limitations for 
diagnosis, due to its low sensitivity. Autoimmune 
neutropenia is common in the first two years of life and 
usually presents itself in apparently healthy children 
[17]. Usually, there is no specific physical examination 
for children with autoimmune neutropenia. However, 
there may be findings for mouth ulcers, ear infections, 
or upper respiratory tract infections [4, 18]. Generally, 
in these cases, unlike severe peripheral neutropenia, 
severe infections are not observed. Sometimes these 
children may also have a previous viral illness But 
showed no association between parvovirus infection and 
autoimmune neutropenia In children. [4]. At an early age, 
congenital factors and family history of neutropenia 
might be associated with recurrent fever and infections. 
A study by Fioredda et al. revealed that severe infectious 
side effects in autoimmune neutropenia were less 
common than in genetic neutropenia [19]. It is important 
to investigate the cause of neutropenia, since it can be 
helpful to predict the severity and guide both medical 
interventions and healthcare guidance for families. 
Secondary causes of autoimmune neutropenia are more 
common in children and adults [17]. Factors that 
contribute to secondary neutropenia include connective 
and autoimmune tissue diseases, medications, and 
malignancies [18]. The cause of secondary neutropenia 
is often multifactorial; anti- neutrophil antibodies, other 
mechanisms of neutrophil peripheral destruction , and 
the reduced granulopoiesis in the bone marrow might 
have roles in this type of neutropenia [20]. Splenomegaly 
and other physical findings, along with another 
cytopenia, should be considered in bone marrow 
examination to find the cause of malignancy and 
myelodysplasia [3]. Both Felty syndrome (including 
rheumatoid arthritis, splenomegaly, and neutropenia) and 
systemic lupus erythematosus are autoimmune diseases 
that are usually associated with neutropenia in adults. 
Nutropenia is well described for lupus erythematosus 
systemic disease. In a prospective study, 47% of patients 
with lupus-erythematosus were affected by systemic 
neutropenia [21]. This could be due to the similarity of 
neutrophil and Ro /SSA surface antigens in patients with 
systemic lupus erythematosus who have Ro/SSA 
antibodies [18]. Interestingly, anti-neutrophil antibodies 
have been identified in patients with systemic lupus 
erythematosus with or without the presence of 
neutropenia [22]. In Felty syndrome, neutropenia may be 
caused by immune complex, anti-neutrophile antibodies, 
which binds to neutrophil antigens and inflammatory 
cytokines (interferon-alpha, interferon-gamma), which 
can lead to neutrophil bone marrow production [18, 20]. 
In felty syndrome secondary autoimmune neutropenia 
can also be caused by large granular lymphocytic 
leukemia (LGL) which is a clonal malignancy of CD8+ 
T cells [18]. The common test for anti-neutrophil 
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antibodies has less usage in clinical procedures due to 
its low sensitivity and specificity [3]. 
Differential diagnosis in 
neutropenia 
Cyclic neutropenia 
 Cyclic neutropenia is a rare autosomal recessive 
disorder, caused by mutations in the neutrophil elastase 
gene. It seems the mutation in this enzyme accelerate 
myeloid cell death; however, the definite mechanism of 
cyclic neutropenia is not completely defined [17]. 
These patients usually present severe neutropenia at the 
site of the oral ulcer and bacterial infection. Bone 
marrow examination shows normal hematopoiesis and 
times of myelocytic maturation arrest in predictable 
intervals. These periods of neutropenia often occur in 
21-day intervals and show severe neutropenia for 3-5 
days, with a rapid reduction in the count of neutrophils 
to more than 1.5×109 cells/L [17, 23]. When the count 
of neutrophils is the lowest in the peripheral blood, 
patients usually suffer from stomatitis, abscesses, and 
severe infections [17]. Due to its cyclic nature, 
diagnosis can be confusing and it requires a continuous 
blood cell count, which must be performed 3 times a 
week for six weeks to record the neutropenia cycles 
regularly [17, 23]. 
Severe Congenital 
Neutropenia 
     Severe congenital neutropenia, also known as 
Castleman disease, is a rare and heterogeneous group of 
diseases that is often associated with severe neutropenia 
and life-threatening infections in early childhood [9]. 
Severe neutropenia is stable, and patients with this 
disease experience deep tissue infections, pneumonia, 
and severe sepsis. Genetic mutations, such as elastase 
and HAX1 mutations were observed in patients with 
severe congenital neutropenia [17]. These patients may 
also experience dysmorphic features and metabolic 
disorders [9, 17, and 24]. Usually, bone marrow shows 
a maturation arrest during the promyelocyte phase [9]. 
About 20-30 percent of these patients are at risk of 
leukemia and myelodysplastic syndrome [17, 25]. 
Other bone marrow failure syndromes should also be 
considered for severe infections, chronic neutropenia, or 
other clinical and laboratory findings. 
Neutropenia associated with 
drug administration and 
nutrient deficiencies 
     Antiepileptic and antibiotics are the most common 
non-chemotherapeutic drugs, leading to drug 
agranulocytosis. The definite mechanism of neutropenia 
is unknown, but findings in anti-neutrophil antibodies in 
some patients show immune processes [26]. Onset after 
exposure can be variable and it may take 1 week to 1 
month after removing the effective agent for the cell 
count to become normal. Vitamin B12, folate, or copper 
deficiency is also considered as a cause of neutropenia 
and this condition is resolved when these nutrients have 
been replaced [9]. 
Autoimmune neutropenia 
associated with other 
autoimmune diseases 
     Evans syndrome, autoimmune hemolytic anemia, and 
immune thrombocytopenic purpura are the most 
common diseases associated with neutropenia in 
children. Systemic lupus erythematosus and other 
autoimmune disorders were reported in patients [9]. 
Usually, children with secondary autoimmune diseases 
are older and female. Since it may be difficult to 
distinguish at primary manifestations, a study suggested 
that detecting anti-neutrophil antibodies may help 
differentiate between primary and secondary 
autoimmune neutropenia. This is because antibodies 
specific to HNA-1a and HNA-1b are found in patients 
with primary autoimmune neutropenia and pan-FcgRIIIb 
in secondary autoimmune neutropenia [14]. 
     History and findings during physical examination are 
the most important aspects of the initial assessment of a 
child with neutropenia. If a review of the child's personal 
and family history does not help, and the physical 
examination is normal, autoimmune neutropenia is 
possible; hence, laboratory evaluation is recommended. 
A complete blood cell count and peripheral blood smear 
evaluation are necessary to prove neutropenia and to rule 
out another cytopenia. Also, morphological 
abnormalities should be performed in all cases. 
Diagnosis and Treatment Management in Patients …                                                                                        Saeidnia M., et al 
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Archives of Medical Laboratory Sciences; Vol 5, No 3, Summer 2019 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. 
5 
Assessment of anti-neutrophilic antibodies can be 
helpful. However, as mentioned, its sensitivity and 
specificity are low for diagnosing autoimmune 
neutropenia. For people with a history of severe 
infections, growth abnormalities, or other unusual 
features, further evaluations are essential. There is no 
need for bone marrow examination for classic 
autoimmune neutropenia, but if production defect is 
presumable, this examination can be helpful. 
Anti-neutrophil antibody 
detection methods 
     For the first time in 1975, Boxer et al. detected 
antineutrophil antibodies, which accelerated the 
destruction of neutrophils. This process was induced by 
the reticuloendothelial system in three out of five 
hospitalized patients [20, 27]. In 1986, this finding was 
confirmed by Hadley et al., and reported a rise in 
antigranulocytes opsonic activity in half of the patients 
with neutropenia, which indicates an immunological 
cause [28]. Previously, animal studies showed that anti-
neutrophil antibodies could lead to neutropenia by 
similar mechanisms of opsonization and increased 
phagocytosis [29]. 
     However, case studies of patients with autoimmune 
neutropenia reported different levels of anti-neutrophil 
antibodies in suspected patients with autoimmune 
neutropenia. This may be due to the antibody titer lower 
than the detectable limit. Besides, the association 
between autoantibody levels and the severity of 
neutropenia was observed in patients who were 
suspected of autoimmune neutropenia [20]. 
     At least two tests are necessary to diagnose anti-
neutrophil antibodies, including an indirect granulocyte 
agglutination test (GAT) and granulocyte 
immunofluorescence test (GIFT) [30]. However, each of 
these tests has its limitations. Indirect granulocyte 
agglutination test can show false-positive results, since 
neutrophils may agglutinate spontaneously [20, 31]. 
However, this test can detect aggregated antibodies, such 
as anti-HNA-3a [32]. Granulocyte immunofluorescence 
test uses fluorescent anti-human neutrophil antibodies to 
detect anti-neutrophil antibodies. However, the 
granulocyte indirect immunofluorescence test exposes 
the patient's serum to control neutrophils and 
autoantibodies are identified, using fluorescent anti-
immunoglobulin antibodies. Evaluation of monoclonal 
antibody-specific immobilization of granulocyte antigen 
(MAIGA) can overcome the false-positive results since 
specific monoclonal antibodies bind to neutrophil gene 
antigens that are adherent to human antibodies [20, 31]. 
However, this assessment is usually unavailable and it 
usually cannot detect the anti-HNA-3a antibodies, which 
plays the most important role in TRALI reactions. 
Recently, a flow cytometric white blood cell 
immunofluorescence test (Flow-WIFT) was performed 
to detect these antibodies. Recent studies showed that 
this test can detect more granulocyte reactive antibodies 
than the immunofluorescence granulocyte test, 
suggesting this test as a screening test in the future [32]. 
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Table 1. General Diagnostic Methods for Childhood Neutropenia [35] 
 Complete Blood Count (CBC) 
Absolute Neutrophil Count(ANC)  
Bone marrow examination to evaluate maturation or maturation arrest in myeloid, megakaryocytes and erythroid 
series 
Performing FISH and karyotype tests on bone marrow samples to assess myelodysplastic risk (MDS), especially 
for chromosomal abnormalities 5 and 7 
Electronic microscopic examination 
anti-neutrophil antibodies detection 
✓ Granulocyte Immunofluorescence Test(GIFT)        
✓ Granulocyte Indirect Immunofluorescence Test (GIIFT) 
✓ Granulocyte Aggregation Test (GAT) 
✓ ELISA test 
✓ Monoclonal Antibody Immobilization of Granulocyte Antigens (MAIGA) 
Immunological tests 
✓ Immunoglobulin measurement(IgA, IgM, IgG, IgE) 
✓ Cell immunity evaluation)proliferation of T-lymphocytes and its subsets, counting and functional 
evaluation of NK cell) 
✓ Anti-nuclear antibodies(C3, C4, CH50) 
Screening of metabolic diseases 
✓ Amino acids screening in plasma and urine 
✓ Vitamin B12 , folic acid and copper levels in serum 
Pancreatic disease findings 
✓  Trypsinogen and iso-amylase level in serum 
 Chromosome breakage test(for diagnosing  Fanconi anemia) 
Serum Muramidase level(for assessing inefficient production of myeloid series) 
 Evaluation of CD55, CD59 factors with flow cytometry test for diagnosing PNH disease. 
Measuring Bone Density(14% of patients  with neutropenia present osteoporosis and low bone density)  
Evaluation of genetic mutation (ELA2, HAX1, LYST GFI-1, WAS), Shwachman–Diamond syndrome 
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Table 2. differential diagnosis for Childhood Neutropenia [9] 
 Infection 
Splenomegaly 
Hepatomegaly 
Growth Retardation 
Anemia/Low 
Platelets 
General Aspects 
Autoimmune 
Neutropenia 
Mild No No No Occasional diagnosis by age 
Leukemia _ Yes No Yes Lactate dehydrogenase 
Secondary Autoimmune 
Neutropenia 
Mild/Moderate Sometimes No Probably yes Another autoimmunity 
Shwachman–Diamond 
Syndrome 
Mild/Moderate Yes Yes Frequently Pancreatic failure 
Glycogen Storage 
Disease type 1 
Moderate Hepatomegaly Yes No Hypoglycemia Ketoacidosis 
Pierson Syndrome Severe 
Probably occurs 
Hepatomegaly 
Yes Yes Lactic acidosis 
Severe Congenital 
Neutropenia 
Severe No Occasionally No Indigestion/Anomalies 
Cyclic Neutropenia Severe No No No Mouth ulcers 
Neutropenia after 
Infection 
_ Probably yes No Probably mild Medical history 
Drug-Mediated 
Neutropenia 
Moderate/Severe No No No Medical history 
 
Autoimmune neutropenia 
treatment 
     Usually, primary autoimmune neutropenia is self-
limited in children and due to the storage of mature 
neutrophils, severe infections are very rare in the bone 
marrow. There is no agreement on the procedure of fever 
examination in children with classic autoimmune 
neutropenia. Multiple therapies such as corticosteroids, 
intravenous immunoglobulin, and granulocyte-
stimulating factor (G-CSF) have been tested and reported 
in articles, but only G-CSF has been effective in 
increasing neutrophil counts [18]. Rituximab, which is a 
monoclonal antibody against CD20, has been used to treat 
patients with autoimmune neutropenia, but has shown 
little efficacy [33]. Recombinant human granulocyte-
colony stimulating factor (G-CSF) stimulates 
demargination of neutrophils from tissue and reduces 
neutrophil apoptosis [18]. This factor is effective in 
increasing the absolute counts of neutrophil to more than 
1×109 cells/L and can prevent infection. In patients with 
cyclic neutropenia and severe congenital neutropenia, 
fatal bacterial infections were observed; hence, G-CSF 
therapy is suggested [17].  
In 2011, “Associazione Italiana di Emato-Oncologia 
Pediatrica (AIEOP)” joined a group of international 
experts to decide for autoimmune neutropenia treatments 
infections, surgery, or timely follow up. The GCSF dose 
depends on the disease condition and the target 
autoimmune neutropenia range, which was set between 
1.0×109 cells/L and 5.0×109 cells/L. In limited cases of 
infection in autoimmune neutropenia, a starting dose was 
recommended 1 to 2 μg/kg/day for one week. If the 
absolute neutrophil count in peripheral blood remains 
lower than 1.0×109 cells/L, increasing 1 to 2 μg every 5-
7 days is justifiable [34].  
In general, patients with autoimmune neutropenia 
respond quickly and strongly to G-CSF therapy due to 
adequate bone marrow supplies. However, treatment with 
G-CSF (especially high doses) can cause significant bone 
pain [3]. To evaluate neutropenia, experts have 
recommended monthly follow up. If neutropenia 
continues, a re-performing test for indirect anti-neutrophil 
antibodies is recommended. Remarkably, the daily use of 
prophylactic antibiotics is not recommended for patients 
with autoimmune neutropenia [34]. Generally, the use of 
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prophylactic antibiotics including cotrimoxazole is not 
recommended for classic autoimmune neutropenia and is 
usually administrated for patients with mild recurrent 
infections and other disorders. As mentioned previously, 
in a retrospective study on 240 infants with primary 
autoimmune neutropenia, 90% had mild infections. 
Although they suffered from severe peripheral 
neutropenia, recovered with systemic antibiotics [4]. 
     In total, 89% of these patients received prophylaxis 
with cotrimoxazole, and prophylaxis was administrated 
only after recurrent infections. Fioredda and colleagues 
reported infection in 40% of patients with autoimmune 
neutropenia, who mainly suffered from skin and soft 
tissue infections [19]. 
Conclusion 
     Autoimmune neutropenia is caused by autoantibodies 
that are produced against neutrophil membrane proteins, 
leading to increased peripheral clearance. Although 
neutropenia is shown as a severe peripheral neutropenia, 
the bone marrow storage and response to bacterial 
infection is generally normal. The clinical course of 
autoimmune neutropenia is usually mild and often 
resolves within 1 to 3 years. Diagnosis remains clinical, 
since it is difficult to detect neutrophil antibodies using 
the current methods. Even in agglutination and 
immunofluorescence combination tests, the identification 
of neutrophil surface antigens is being developed and will 
provide a bright future into the pathophysiology of 
immune neutropenia. Common therapy including 
prophylactic antibiotics or G-CSF is generally not 
recommended and may be used individually for those 
patients with recurrent infections or other clinical 
manifestations. Although autoimmune neutropenia does 
not usually require vigorous medical intervention, the 
patients should be regularly monitored, until the condition 
resolves, and the patient recovers fully. Monitoring 
schedules into the patient's condition including every 1-3 
months complete blood cell counts evaluation and annual 
bone marrow aspiration examination should be performed 
regularly. 
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